股市必读：普洛药业（000739）8月15日董秘有最新回复

Core Viewpoint - The company, Pro Pharmaceutical (000739), is actively engaging in share repurchase and has established a strong presence in the pet medication market, with ongoing projects and a focus on enhancing shareholder returns. Group 1: Share Repurchase and Financial Performance - As of August 15, 2025, Pro Pharmaceutical's stock closed at 16.35 yuan, with a slight increase of 0.68% and a trading volume of 109,600 shares, amounting to a total transaction value of 179 million yuan [1] - The company has repurchased 10.03 million shares, totaling 143 million yuan, and plans to continue the repurchase based on market conditions and funding arrangements [2][3] Group 2: Pet Medication Projects - Pro Pharmaceutical has established long-term partnerships with several leading global pet medication companies, currently managing 49 pet medication projects, with both project numbers and sales revenue showing continuous growth [2] Group 3: Future Projects and Investor Relations - The company is in the design phase for a peptide workshop project with an investment of 300 million yuan, and specific investment strategies will be considered based on market and technological advancements [2] - The company is expected to disclose the progress of ongoing projects in the upcoming 2025 semi-annual report [2] - The company is open to suggestions regarding increasing dividend payouts and share buybacks to enhance investor confidence and returns [2][3]